Eligible patients were randomly allocated in a @:@:@:@ ratio with a centralised , interactive online system to receive either dose-dense chemotherapy ( administered intravenously every @ weeks with pegfilgrastim support ) with fluorouracil plus EC-P ( FEC-P ) or EC-P or to receive standard-interval chemotherapy ( administered intravenously every @ weeks ) with FEC-P or EC-P .